Bharat Parenterals logo

Bharat Parenterals financials and balance sheet

NSE: BPLPHARMABSE: 541096Pharmaceuticals & BiotechnologySmall Cap

Last close ₹1,690.00down ₹86.00 (4.84%)BSE ₹1,662.75

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,776.00.

52-week range of BSE trades to 23 Oct 2026
₹880.25Low, 30 Mar 2026₹2,274.10High, 28 Sep 2026
Market cap
₹1,165 Cr1,597th largest listed
P/E
Owners' profit not stated
P/B
3.6
Dividend yield
0.06%
ROCE
−5.2%
Debt to equity
0.47
Volume, NSE
3,08940.3% delivered

9 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Bharat Parenterals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹345 Cr, year to Mar 2026A loss in 2 of the 9 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue345
  2. Materials and goods−191
  3. Employee costs−67
  4. Other expenses−71
  5. Operating profit16
  6. Depreciation−34
  7. Other income+9.5
  8. One-off items0.0
  9. Finance costs−13
  10. Profit before tax−21
  11. Tax−5.9
  12. Net profit−27

What the company owns

  • Plant, investments and other assets₹361 Cr
  • Receivables₹151 Cr
  • Inventory₹85 Cr
  • Cash and bank₹12 Cr
  • Current investments₹5 Cr

What pays for it: net worth and liabilities

  • Net worth₹312 Cr
  • Borrowings₹146 Cr
  • Other liabilities₹92 Cr
  • Owed to suppliers₹64 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Bharat Parenterals quarterly results

₹ croreMar 2018Mar 2019Filed 6 JunMar 2020Filed 20 JunMar 2021Filed 5 JunMar 2022Filed 9 JunMar 2023Filed 8 JunMar 2024Filed 24 JulMar 2025Filed 5 OctMar 2026Filed 18 May
Revenue from operations139220228205212218257340345
–191200179184198235338330
Materials and goods bought88140149134136137158185191
Employee costs–1516151518235067
Other expenses–35363033435410371
Operating profit before depreciation–292825282022316
Operating margin–13.2%12.3%12.3%13.0%9.1%8.7%0.8%4.6%
Materials, % of revenue–64.0%65.3%65.6%64.2%63.1%61.5%54.5%55.4%
Employee costs, % of revenue–7.0%6.8%7.2%7.2%8.3%8.9%14.6%19.5%
Other expenses, % of revenue–15.9%15.6%14.9%15.5%19.6%20.9%30.1%20.5%
Depreciation and amortisation–6667693534
Operating profit after depreciation–232219211413−33−18
Other income71311981291210
Finance costs11111231313
One-off items000000000
Profit before tax13353327282419−34−21
41397788–6
9212420211611−44−27
Other comprehensive income–00000001
Total comprehensive income–212420211610−43−27
Net margin6.6%9.7%10.6%9.9%9.8%7.2%4.1%−12.8%−7.9%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2018: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given. Belonging to the company's shareholders is left blank for the year to Mar 2024: the filing's earnings per share does not match the profit it states, and cannot be multiplied back into the owners' profit because the share it leaves the other owners is more than 10 points from the share the company's other periods state. Tax is left blank for the year to Mar 2025: profit before tax less the tax charge stated does not come to the profit after tax the same statement states, so the tax charge is not shown. Belonging to outside owners of subsidiaries is left blank for the year to Mar 2025: the filing states 0 for this share both for the period and for the year so far, which the form also writes for a line it does not fill, while the company's other filings for the same year show it was not 0 over those months.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 6 JunMar 2020Filed 20 JunMar 2021Filed 5 JunMar 2022Filed 9 JunMar 2023Filed 8 JunMar 2024Filed 24 JulMar 2025Filed 5 OctMar 2026Filed 18 May
94118144170218238339312
94118144166183197331322
Share capital66666677
Reserves88112138160177191324315
Belonging to outside owners of subsidiaries000435418−11
3110185084180146
61664442120190219157
431114137590144
Total assets159188199226350504649613
41565182166244293300
118132148144184260356313
Net debt−11−10−3524072118129
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 5 JunMar 2022Filed 9 JunMar 2023Filed 8 JunMar 2024Filed 24 JulMar 2025Filed 5 OctMar 2026Filed 18 May
31−122−5−2738
385315−1748
0−28−2−29−2921
Receivables12−50−28−2517
Inventories62−17−24−10−13
Payables−16−2−5915−10
Other working capital−1−221914−826
Tax paid−7−60−9−11−10
Interest paid000000
Capital spending639921042940
Free cash flow25−40−70−109−56−2
−48−7−78−105−1379
8961110156−47
Dividends paid000011
Shares bought back000000
Shares issued00001470
Net change in cash−8241−81
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Bharat Parenterals dividend history

₹ per shareMar 2018Mar 2019Filed 6 JunMar 2020Filed 20 JunMar 2021Filed 5 JunMar 2022Filed 9 JunMar 2023Filed 8 JunMar 2024Filed 24 JulMar 2025Filed 5 OctMar 2026Filed 18 May
Earnings per share₹15.91₹37.08₹42.14₹35.59₹36.67₹28.40₹8.65−₹66.64−₹39.62
Diluted earnings per share₹15.91₹37.08₹42.14₹35.59₹36.67₹28.40₹8.65−₹66.64−₹39.62
Dividend per share–––––₹0.75₹1.00₹1.00₹1.00
Book value per share–₹164.07₹206.28₹251.43₹287.15₹316.79₹338.97₹479.93₹467.55
Dividend payout–––––2.6%–––
Shareholder yield–––0.0%−0.2%0.0%0.0%−21.6%0.1%
Market cap at the year end (₹ crore)11712681192196194648681620

Ratios

Consolidated, years to March.Bharat Parenterals PE ratio and valuation

RatioMar 2019Filed 6 JunMar 2020Filed 20 JunMar 2021Filed 5 JunMar 2022Filed 9 JunMar 2023Filed 8 JunMar 2024Filed 24 JulMar 2025Filed 5 OctMar 2026Filed 18 May
Revenue growth58.5%3.9%−10.3%3.6%2.8%18.1%32.3%1.5%
Operating profit growth–−2.8%−10.1%9.5%−28.1%12.5%−87.9%485.8%
Net profit growth133.1%13.7%−15.9%2.5%−24.5%−33.1%––
Earnings per share growth133.1%13.6%−15.5%3.0%−22.6%−69.5%––
22.6%22.8%15.6%13.6%9.4%–−16.5%−2.5%
–0.2 pts−7.2 pts−2.0 pts−4.2 pts––14.0 pts
From the net margin–2.1 pts−1.3 pts−0.1 pts−3.3 pts––13.5 pts
From asset turnover–−1.1 pts−4.2 pts−0.9 pts−2.5 pts––0.2 pts
From borrowing–−0.8 pts−1.7 pts−1.0 pts1.6 pts––0.3 pts
Return on capital employed23.5%18.7%12.5%11.2%5.2%4.1%−6.3%−4.0%
Cash conversion––153.9%−5.1%137.8%−44.8%––
Interest cover26.225.824.923.66.44.1––
Debt to equity0.030.010.070.100.230.350.530.47
Receivable days106127121126188201184159
Inventory days59716156100142142162
Payable days831047164155138146122
Cash conversion cycle, days8293111118134204180199
Working capital days7688108157156201191172
Asset turnover1.381.321.061.000.760.600.590.55
Assets per rupee of net worth1.691.631.471.371.652.252.181.93
Sales per rupee of plant6.467.194.725.335.291.231.711.71
Capital spending to depreciation––0.975.8515.5811.560.821.17
Plant being built, % of plant in use3.1%38.3%1.0%64.5%240.4%11.4%15.2%16.8%
Interest cover is left blank for the years to Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−1.3%
Cash from operations against operating profit
242.5%
Measure10 years5 years3 years
Revenue growth, yearly rate–11.0%16.6%
Return on equity, average–1.0%−9.5%
Return on capital employed, average–2.0%−2.1%
Operating margin, average–7.2%4.7%
Net margin, average4.1%0.1%−5.5%
Asset turnover, average–0.700.58
Cash conversion cycle, days, average–167194
Debt to equity, average–0.340.45

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations27638
Cash from investing−317−2339
Cash from financing289219−47
Capital spending30417340
Dividends paid221
Shares bought back000
Shares issued for cash1481480
Borrowings raised11911446
Borrowings repaid17514280

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––536334
Altman Z-scorePublished threshold 1.81–4.493.775.195.012.672.832.692.77
Beneish M-scorePublished threshold −1.78–––−3.04−0.31−2.04−2.29−2.23−2.95
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––19.1613.4324.9428.1020.95−11.89
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––0.910.34––
Receivables growth less revenue growthOur threshold 0 percentage points––20.31−4.204.6150.337.74−10.82−13.76
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––21.96−12.33−8.7981.2347.26−0.0814.55
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––−2.17−0.3610.91−4.278.101.423.16
Assets under construction, years of additionsOur threshold 2 years of additions––3.330.028.4113.530.131.220.92
Effective tax ratePublished threshold 17.16 per cent28.7438.5826.3625.1125.3633.2543.96––
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––5.0233.25−6.57––
A threshold marked as ours has no published figure; it is the line we read the check against.